ORTHO/CHIRON HCV 3.0 HEPATITIS ANTIBODY SCREENING TEST COULD DETECT UP TO 150 ADDITIONAL INFECTIOUS UNITS PER YEAR -- FDA CMTE. MEMBERS SUGGEST APPROVAL
This article was originally published in The Gray Sheet
Executive Summary
Use of Ortho and Chiron's jointly developed Ortho HCV 3.0 ELISA hepatitis C virus antibody screening test could lead to the detection among voluntary donors of up to 150 more infectious units per year than are identified by screening with the firms' currently available HCV 2.0 test, according to data presented by Ortho at a March 21 meeting of FDA's Blood Products Advisory Committee in Bethesda, Maryland.